바이오인

The global biotechnology industry rebounded strongly in 2013. Public companies achieved double digit revenue growth and there was a sharp rise in funds raised. Product successes have boosted revenues, drawn investors and motivated large companies to invest strongly in R&D.

However, much of the industry’s growth was driven by a relatively small group of commercial stage companies, increasing the urgency for the rest of the industry to achieve greater efficiency in their drug development efforts.

Key findings

Several findings emerged in our analysis of key performance indicators:

Revenue climbs: Companies in the industry’s established biotech centers (the US, Europe, Canada and Australia) generated revenues of US$98.8b, a 10% increase from 2012. However, virtually all of this growth came from 17 US-based “commercial leaders,” defined as companies with revenues in excess of US$500m. European topline growth slows, but profits soar.

R&D spending rebounds: R&D spending rebounded forcefully, up 14% from the prior year, driven primarily by a 20% increase in spending in the US. This is the first time since the onset of the global financial crisis that R&D growth has outpaced revenue growth.

Net income slips: Net income declined by US$0.8b, driven in part by the US$3.7b increase in R&D expenditures during the year.

Market capitalization skyrockets: Market capitalization grew 65% to US$791.8b, catalyzed by strong performances from commercial leaders, which increased enthusiasm in the sector overall.

.......(계속)

☞ 자세한 내용은 내용바로가기 및 첨부파일을 참고하시기 바랍니다.